To examine the impact of H3K27me3 in the transcriptional silencing of the TERT locus in neuroblastoma, we treated neuroblastoma cell lines with long telomeres (SKNFI, SKNMM, CHLA-90, and LAN6) and MYCN-amplified neuroblastoma cell lines with short telomeres (SKNBE2 and NB5) with the FDA-approved EZH2 inhibitor, Tazemetostat, and measured TERT expression. The gene discussed is MYCN; the disease is neuroblastoma.